Clinical Trial Update: A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma [Phase 1]

View source ↗

Summary

Treeline Biosciences is conducting a Phase 1 study of TLN-254 in participants with relapsed or refractory T-cell lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• T-cell Lymphoma

Drugs mentioned

• TLN-254

Snippet

Sponsor: Treeline Biosciences, Inc. | Conditions: Lymphoma | Phase 1 | Status: RECRUITING